SIGA gets $15M Canadian defense contract for oral TPOXX, discloses CSO retirement
SIGA Technologies reported financial results for the third quarter and first nine months of 2026 on November 9, 2026, alongside operational updates on its smallpox antiviral TPOXX.
SIGA Technologies reported financial results for the third quarter and first nine months of 2026 on November 9, 2026, alongside operational updates on its smallpox antiviral TPOXX.
The company said in October, Canada's Department of National Defence awarded SIGA a contract for oral TPOXX purchases that could total approximately $15 million through March 31, 2031, with about $9 million in firm commitments over the first three years and about $6 million subject to the department's option.1 CEO Diem Nguyen said the company is continuing to work with the U.S. government toward a new TPOXX procurement contract while treating its international business as an important part of its strategy, and is pursuing additional government customers to diversify revenue over time.1
On delivery activity, SIGA said it shipped approximately $13 million of oral TPOXX to two international customers during the first nine months of 2026,1 and separately delivered about $26 million of IV TPOXX to the U.S. Strategic National Stockpile under the 19C contract, completing the final procurement order under that agreement.1
The company also disclosed a leadership change: Chief Scientific Officer Dennis Hruby is retiring effective November 9, 2026, after more than 30 years with the company, and will continue in an advisory role.1
Financially, SIGA posted total revenues of $1.3 million for the third quarter versus $2.6 million a year earlier, and $48.6 million for the nine-month period versus $90.8 million in the prior-year period, with a quarterly net loss of $2.9 million compared with a $6.4 million loss a year earlier, while nine-month net income was $6.1 million versus $28.7 million.1 As of September 30, 2026, the company reported cash and cash equivalents of $116,380,386, down from $154,966,414 at the end of 2025.1 SIGA also noted that it paid a special cash dividend of $0.60 per share on April 23, 2026, to shareholders of record as of April 7, 2026.1
Fact check notes
- Checker's noteThe summary claims a 'swing to a quarterly net loss,' but both Q3 2026 and Q3 2025 were net losses ($2.9M and $6.4M respectively); the loss narrowed, it did not swing from profit to loss.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Where the check questioned a sentence, its note is shown above. Not investment advice.